Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) by All Transretinoic Acid (ATRA) Combined with Chemotherapy: The European Experience

References

• Huang M., Yu-Chen Y., Shu-Rong C., et al. Use of all trans retinoic acid in the treatment of acute promyelocyte leukemia. Blood 1988; 72: 567–72
   PubMed Web of Science ®Google Scholar
• Castaigne S., Chomienne C., Daniel M.T., Berger R., Fenaux P., Degos L. All trans retinoic acid as a differentiating therapy for acute promyelocytic leukemias. I. Clinical results. Blood 1990; 76: 1704
   PubMed Web of Science ®Google Scholar
• Warrel R.P., Frankel S.R., Miller W., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all trans retinoic acid). N. Engl. J. Med. 1991; 324: 1385–93
   PubMed Web of Science ®Google Scholar
• Chen Z.Y., Xue Y.Q., Zhang R., et al. A clinical and experimental study on all trans retinoic acid treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413–1419
   PubMed Web of Science ®Google Scholar
• Fenaux P., Castaigne S., Chomienne C., Dombret H., Degos L. All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 1992; 6: 64–67
   PubMed Web of Science ®Google Scholar
• Degos L., Chomienne C., Daniel M.T., Berger R., Dombret H., Fenaux P., Castaigne S. Treatment of first relapse in acute promyelocytic leukaemia with all trans retinoic acid. Lancet 1990; ii: 1440
   Web of Science ®Google Scholar
• Fenaux P., Castaigne S., Dombret H., et al. All transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992; 80: 2176–81
   PubMed Web of Science ®Google Scholar
• Chomienne C., Ballerini P., Balitrand N., Daniel M.T., Fenaux P., Castaigne S., Degos L. All trans retinoic acid in promyelocytic leukemias. II. In vitro studies structure function relationship. Blood 1990; 76: 1710
   PubMed Web of Science ®Google Scholar
• Elliott S., Taylor K., White S., et al. Proof of differentiating mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 1991; 79: 1916–1919
   Web of Science ®Google Scholar
• Ohashi H., Ichikawa A., Takagi N., et al. Remission induction of acute promyelocytic leukemia by all-trans-retinoic acid: molecular evidence of restoration of normal hematopoiesis after differentiation and subsequent extinction of leukemic clone. Leukemia 1992; 6: 859–862
   PubMed Web of Science ®Google Scholar
• Tallman M.S., Kwaan H.C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79: 543–552
   PubMed Web of Science ®Google Scholar
• Frankel S.R., Eardley A., Lauwers G., et al. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann. Int. Med. 1992; 117: 292–296
   PubMed Web of Science ®Google Scholar
• Vadhat L., Eardley A., Heller G., Warrell R. Leucocytosis, the retinoic acid syndrome and early mortality in APL: when is chemotherapy needed during remission induction with ATRA. Blood 1993; 82: 192a, (abstr.). suppl. 1
   PubMed Web of Science ®Google Scholar
• Wiley J.S. ATRA: new differentiation therapy for APL International Symposium on Retinoids in Hematological Malignancies, Shangaï, 1993; 19
   Google Scholar
• Ohno R., Yoshida H., Fukuta H., et al. Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 1993; 7: 1722–1727
   PubMed Web of Science ®Google Scholar
• Sun G.L. Follow-up of 524 patients with APL after CR induced by ATRA. International Symposium on Retinoids in Hematological Malignancies, Shangaï, 1993; 16
   Google Scholar
• Frankel S.R., Eardley A., Heller G., et al. All-trans retinoic acid for acute promyelocytic leukemia. Ann. Intern. Med. 1994; 120: 278–286
   PubMed Web of Science ®Google Scholar
• Castaigne S., Lefebvre P., Chomienne C., et al. Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia. Blood 1993; 82: 3560–3563
   PubMed Web of Science ®Google Scholar
• Mahmoud H.H., Hurwitz C.A., Roberts W.M., et al. Tretinoin toxicity in children with acute promyelocytic leukaemia. Lancet 1993; 342: 1394–95
   PubMed Web of Science ®Google Scholar
• Fenaux P., Tertian G., Castaigne S., et al. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. J. Clin. Oncol. 1991; 9: 1556–1561
   PubMed Web of Science ®Google Scholar
• Fenaux P., De Deley M.C., Castaigne S., et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993; 82: 3241–49
   PubMed Web of Science ®Google Scholar
• Fenaux P., Chastang C., Chomienne C., Degos L. All transretinoic acid (ATRA) in combination with chemotherapy improves survival in newly diagnosed acute promyelocytic leukemia (APL). Lancet, (in press)
   Google Scholar
• Douer D., Koeffler P. Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro. Exp. Cell. Res. 1982; 138: 193–198
   PubMed Web of Science ®Google Scholar
• Delva L., Comic M., Balitrand N., Guidez F., Miclea J.M., Delmer A., Teillet F., Fenaux P., Castaigne S., Degos L., Chomienne C. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: a study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993; 82: 2175–2181
   PubMed Web of Science ®Google Scholar
• Muindi J., Frankel S.R., Miller W.H., et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood 1992; 79: 299–303
   PubMed Web of Science ®Google Scholar
• Francis P.A., Rigas J.R., Muindi J., Kris M.G., Young C.W., Warrel R.P. Modulation of all-trans retinoic acid (RA) pharmacokinetis by a cytochrome p450 enzyme system inhibitor. Proc. Am. Soc. Clin. Oncol. 1992; 11: 108
   Google Scholar
• Miller V.A., Rigas J.R., Kris M.G., Muindi J.R.F., Young C.W., Warrel R.P. Use of liarozole, a novel inhibitor of cytochrome p450 oxidases, to modulate catabolism of all-trans retinoic acid. Proc. Am. Soc. Clin. Oncol. 1993; 12: 159
   Google Scholar
• Vaickus L., Villalona-Calero M.A., Caliguiri T. Acute proganulocytic leukemia (APL): possible in vivo differentiation by granulocyte colony-stimulating factor (G-CSF). Leukemia 1993; 7: 1680–1681
   PubMed Web of Science ®Google Scholar
• Nakajima K., Hatake K., Miyata T., Muroi K., Komatsu N., Miura Y. Acute promyelocytic leukaemia, tretinoin, and granulocyte colony-stimulating factor. Lancet 1994; 343: 173
   PubMed Web of Science ®Google Scholar
• Adamson P.C., Boylan J.F., Balis F.M., Murphy R., Godwin K., Gudas J., Poplack D. Time course in induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Res. 1993; 53: 472–276
   PubMed Web of Science ®Google Scholar
• Marty M., Ganem G., Fischer J., et al. Leucémie aiguâ promyélocytaire: étude rétrospective de 119 malades traités par daunorubicine. Nouv. Rev. Fr. Hematol. 1984; 24: 371–78
   Google Scholar
• Kantarjian H., Keating M., Walters R., et al. Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer 1987; 59: 1258
   PubMed Web of Science ®Google Scholar
• LoLoco F., Diverio D., Pandolfi P.P., et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992; 340: 1437–1438
   PubMed Web of Science ®Google Scholar